This Article Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Correa, P. Articles by Westin, G. Search for Related Content PubMed PubMed Citation Articles by Correa, P. Articles by Westin, G.

Increased 25-Hydroxyvitamin D₃ 1-Hydroxylase and Reduced 25-Hydroxyvitamin D₃ 24-Hydroxylase Expression in Parathyroid Tumors: New Prospects for Treatment of Hyperparathyroidism with Vitamin D

Department of Surgical Sciences, Endocrine Unit, Uppsala University Hospital, SE-751 85 Uppsala, Sweden

Address correspondence to: Gunnar Westin, M.D., Department of Surgical Sciences, Endocrine Unit, Uppsala University, Klinisk forskningsavdelning 2, ingang 70, plan 3, lab 9, SE-751 85 Uppsala, Sweden.

Abstract

Vitamin D analogues are in clinical use for prevention and treatment of secondary hyperparathyroidism (HPT) in chronic renal failure. Despite recent advances there is a need for vitamin D derivatives with maintained parathyroid hormone suppressive activity and less hypercalcemic and hyperphosphatemic toxicity. Here we show coincident increased expression of the vitamin D activating enzyme 25-hydroxyvitamin D₃ 1-hydroxylase (1-hydroxylase) and reduced expression of the 1,25(OH)₂D₃ catabolizing enzyme 25-hydroxyvitamin D₃ 24-hydroxylase (24-hydroxylase) in the majority of investigated parathyroid adenomas and secondary hyperplastic glands. In addition, this relationship was found for the mitochondrial CYP27A enzyme (25-hydroxylase), a potential physiological vitamin D₃ 25-hydroxylase. These findings should be considered in future development of vitamin D analogues for treatment of HPT.

This article has been cited by other articles:

				M. F. Holick Vitamin D Deficiency N. Engl. J. Med., July 19, 2007; 357(3): 266 - 281. [Full Text] [PDF]

				M. van Driel, M. Koedam, C. J. Buurman, M. Hewison, H. Chiba, A. G. Uitterlinden, H. A. P. Pols, and J. P. T. M. van Leeuwen Evidence for auto/paracrine actions of vitamin D in bone: 1{alpha}-hydroxylase expression and activity in human bone cells FASEB J, November 1, 2006; 20(13): 2417 - 2419. [Abstract] [Full Text] [PDF]

				B Moosgaard, P Vestergaard, L Heickendorff, F Melsen, P Christiansen, and L Mosekilde Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur. J. Endocrinol., August 1, 2006; 155(2): 237 - 244. [Abstract] [Full Text] [PDF]

				A. J. Brown, C. S. Ritter, J. C. Knutson, and S. A. Strugnell The vitamin D prodrugs 1{alpha}(OH)D2, 1{alpha}(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells Nephrol. Dial. Transplant., March 1, 2006; 21(3): 644 - 650. [Abstract] [Full Text] [PDF]

				A. Grey, J. Lucas, A. Horne, G. Gamble, J. S. Davidson, and I. R. Reid Vitamin D Repletion in Patients with Primary Hyperparathyroidism and Coexistent Vitamin D Insufficiency J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2122 - 2126. [Abstract] [Full Text] [PDF]